These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 17437612)

  • 61. Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotype.
    Zhou Y; Claflin SB; Stankovich J; van der Mei I; Simpson S; Roxburgh RH; Kalincik T; Blizzard L; Lugaresi A; Alroughani R; Sajedi SA; Butzkueven H; Pucci E; Spitaleri D; Granella F; Cristiano E; Yamout B; Hughes S; Gouider R; Sánchez Menoyo JL; Olascoaga J; McGuigan C; Shaw C; Kermode AG; Kasa K; Al-Harbi T; Altintas A; Laureys G; Fragoso Y; Hardy TA; Csepany T; Sirbu CA; Decoo D; Sas A; Alvarez-Cermeño JC; Kotkata K; Millán-Pascual J; Taylor BV
    Mult Scler; 2020 Nov; 26(13):1765-1774. PubMed ID: 31668127
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Lipoprotein markers associated with disability from multiple sclerosis.
    Gafson AR; Thorne T; McKechnie CIJ; Jimenez B; Nicholas R; Matthews PM
    Sci Rep; 2018 Nov; 8(1):17026. PubMed ID: 30451923
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Disability in multiple sclerosis is associated with age and inflammatory, metabolic and oxidative/nitrosative stress biomarkers: results of multivariate and machine learning procedures.
    Flauzino T; Simão ANC; de Carvalho Jennings Pereira WL; Alfieri DF; Oliveira SR; Kallaur AP; Lozovoy MAB; Kaimen-Maciel DR; Maes M; Reiche EMV
    Metab Brain Dis; 2019 Oct; 34(5):1401-1413. PubMed ID: 31302813
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The level of isoprostanes as a non-invasive marker for in vivo lipid peroxidation in secondary progressive multiple sclerosis.
    Miller E; Mrowicka M; Saluk-Juszczak J; Ireneusz M
    Neurochem Res; 2011 Jun; 36(6):1012-6. PubMed ID: 21399906
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Relationship between symptom change, relapse activity and disability progression in multiple sclerosis.
    Liu Y; Morgan C; Hornung L; Tyry T; Salter AR; Agashivala N; Belletti DA; Kim E; Fox RJ; Cofield SS; Cutter GR
    J Neurol Sci; 2016 Mar; 362():121-6. PubMed ID: 26944131
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Investigation of the prognostic value of adipokines in multiple sclerosis.
    Çoban A; Düzel B; Tüzün E; Tamam Y
    Mult Scler Relat Disord; 2017 Jul; 15():11-14. PubMed ID: 28641765
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Assessment of plasma biomarkers for their association with Multiple Sclerosis progression.
    Jacob S; Al-Kandari A; Alroughani R; Al-Temaimi R
    J Neuroimmunol; 2017 Apr; 305():5-8. PubMed ID: 28284345
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Progression index and disability status in multiple sclerosis: a resurvey of 207 patients in central Poland.
    Cendrowski WS
    Schweiz Arch Neurol Psychiatr (1985); 1986; 137(4):5-13. PubMed ID: 2428106
    [TBL] [Abstract][Full Text] [Related]  

  • 69. New Multiple Sclerosis Disease Severity Scale Predicts Future Accumulation of Disability.
    Weideman AM; Barbour C; Tapia-Maltos MA; Tran T; Jackson K; Kosa P; Komori M; Wichman A; Johnson K; Greenwood M; Bielekova B
    Front Neurol; 2017; 8():598. PubMed ID: 29176958
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Oxidant stress in the pathogenesis of multiple sclerosis].
    Lutskiĭ MA; Esaulenko IE
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006; Spec No 3():26-30. PubMed ID: 17172232
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS.
    Kalincik T; Kister I; Bacon TE; Malpas CB; Sharmin S; Horakova D; Kubala-Havrdova E; Patti F; Izquierdo G; Eichau S; Ozakbas S; Onofrj M; Lugaresi A; Prat A; Girard M; Duquette P; Grammond P; Sola P; Ferraro D; Alroughani R; Terzi M; Boz C; Grand'Maison F; Bergamaschi R; Gerlach O; Sa MJ; Kappos L; Cartechini E; Lechner-Scott J; van Pesch V; Shaygannejad V; Granella F; Spitaleri D; Iuliano G; Maimone D; Prevost J; Soysal A; Turkoglu R; Ampapa R; Butzkueven H; Cutter G;
    Mult Scler; 2022 Oct; 28(11):1752-1761. PubMed ID: 35373638
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Right-Sided clinical findings are worse prognostic factor in Multiple Sclerosis patients?
    Varoglu AO; Balkuv E
    Neurosciences (Riyadh); 2020 Apr; 25(2):97-103. PubMed ID: 32351246
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Lipid peroxidation products and antioxidant proteins in plasma and cerebrospinal fluid from multiple sclerosis patients.
    Hunter MI; Nlemadim BC; Davidson DL
    Neurochem Res; 1985 Dec; 10(12):1645-52. PubMed ID: 4088434
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Rapid disease course in African Americans with multiple sclerosis.
    Kister I; Chamot E; Bacon JH; Niewczyk PM; De Guzman RA; Apatoff B; Coyle P; Goodman AD; Gottesman M; Granger C; Jubelt B; Krupp L; Lenihan M; Lublin F; Mihai C; Miller A; Munschauer FE; Perel AB; Teter BE; Weinstock-Guttman B; Zivadinov R; Herbert J
    Neurology; 2010 Jul; 75(3):217-23. PubMed ID: 20644149
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Does long-term partial sodium channel blockade alter disease progression in MS? Evidence from a retrospective study.
    Counihan TJ; Duignan JA; Gormley G; Saidha S; Dooley C; Newell J
    Ir J Med Sci; 2014 Mar; 183(1):117-21. PubMed ID: 24287594
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Pregnancy and multiple sclerosis].
    Koliba P; Zapletalová O; Petzel M
    Ceska Gynekol; 2005 Nov; 70(6):426-30. PubMed ID: 17955793
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Acetate correlates with disability and immune response in multiple sclerosis.
    Pérez-Pérez S; Domínguez-Mozo MI; Alonso-Gómez A; Medina S; Villarrubia N; Fernández-Velasco JI; García-Martínez MÁ; García-Calvo E; Estévez H; Costa-Frossard L; Alvarez-Cermeño JC; Luque-Garcia JL; Arroyo R; Villar LM; Alvarez-Lafuente R
    PeerJ; 2020; 8():e10220. PubMed ID: 33240608
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [The metabolic characteristics of patients with multiple sclerosis].
    Shtybel' VH
    Lik Sprava; 1998; (5):89-91. PubMed ID: 9793316
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Low leucocyte myeloperoxidase activity in patients with multiple sclerosis.
    Ramsaransing G; Teelken A; Prokopenko VM; Arutjunyan AV; De Keyser J
    J Neurol Neurosurg Psychiatry; 2003 Jul; 74(7):953-5. PubMed ID: 12810789
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course.
    Weinshenker BG; Bass B; Rice GP; Noseworthy J; Carriere W; Baskerville J; Ebers GC
    Brain; 1989 Dec; 112 ( Pt 6)():1419-28. PubMed ID: 2597989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.